Overview

DLBS1033 for the Treatment of Acute Ischemic Stroke

Status:
Terminated
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, double-blind, and controlled clinical study to investigate the effects of DLBS1033 in conjunction with standard therapy compared to standard therapy alone in acute ischemic stroke patients.
Phase:
Phase 3
Details
Lead Sponsor:
Dexa Medica Group